Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

by September 28, 2023
September 28, 2023
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

Laverock Therapeutics, established to commercialise the gene editing induced gene silencing platform for all human therapeutic applications has announced it has expanded its seed funding round to £13.5M.

This investment was led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.

The funding will enable further development of the GEiGS technology and progression of Laverock’s programmes in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumour responsive T-cell and macrophage based immune therapies, through to in vitro and in vivo validation. A key part of this next phase will be bringing on new members of the team and expanding lab facilities.

David Venables, CEO of Laverock, commented: “GEiGS is already showing significant potential to transform the safety and efficacy of advanced therapies and we are excited that this new investment will allow us to progress towards pre-clinical candidate selection. We’re pleased to welcome such an experienced group of investors on board, bringing extensive sector expertise which will help us to grow as a company and accelerate the development of targeted, responsive treatments.”

Elizabeth Klein, Investment Director at Calculus, said: “We are delighted to support Laverock and its exceptional management team, led by CEO David Venables, as the company embarks on its next phase of expansion, pioneering a new era of programmable advanced therapies. We backed David’s previous venture, Synpromics, which delivered an exceptional return for Calculus investors in 2019. Laverock’s ambitious plans hold tremendous potential for the healthcare sector, and we are excited to be part of the journey.”

Read more:
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

0
FacebookTwitterGoogle +Pinterest
previous post
Ditching the crystal ball on a potential government shutdown
next post
One in five SME owners planning to sell part or all of business by 2025

You may also like

UK car market sees first million sales since...

July 4, 2024

Google faces antitrust trial over ad dominance as...

September 10, 2024

40,000 UK SMEs seek finance as spiralling costs...

September 13, 2022

Former BoE governor Lord King thinks austerity could...

October 24, 2022

Heather Mills rescues vegan food empire after blaming...

January 22, 2024

Record number of Britons file tax returns on...

December 30, 2022

More than a million work days lost to...

January 3, 2023

London cements top 10 global position as tech...

October 12, 2023

Tractors Gather at Parliament in Farmer Go-Slow Protest

March 26, 2024

Call for all Post Office convictions to be...

December 15, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Trump warns of ‘serious consequences’ if Elon Musk funds Democrats

      June 7, 2025
    • Musk jokes about reconsidering stance on Big Beautiful Bill after Schiff’s praise

      June 7, 2025
    • Musk deletes explosive posts about Trump and Epstein files

      June 7, 2025
    • House witness flips script on Dem who ambushed him during hearing with unearthed tweet: ‘Iceberg is ahead’

      June 7, 2025
    • Call with China’s Xi, and Trump-Musk exchange fueled barbs during 20th week in office

      June 7, 2025
    • Trump’s conservative allies warn Congress faces critical ‘test’ with $9.4B spending cut proposal

      June 7, 2025

    Categories

    • Business (8,152)
    • Investing (2,019)
    • Politics (15,568)
    • Stocks (3,136)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved